Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNTX NASDAQ:EXOZ NASDAQ:FLNA NASDAQ:LEXX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTXContext Therapeutics$0.62-0.1%$1.53$0.55▼$3.62$57.31M1.754.25 million shs1.74 million shsEXOZeXoZymes$7.00+9.9%$8.61$6.13▼$18.40$58.67M2.7314,360 shs2,736 shsFLNACassava Sciences$1.09-5.2%$1.28$1.07▼$4.98$55.55M-0.73339,026 shs532,720 shsLEXXLexaria Bioscience$0.59-1.3%$0.60$0.46▼$1.55$14.75M0.3459,379 shs50,614 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTXContext Therapeutics-0.14%-11.01%-55.19%-75.18%-14.93%EXOZeXoZymes+9.89%-7.77%-1.41%-35.42%-28.64%FLNACassava Sciences-5.22%-16.79%-12.80%-31.45%-49.54%LEXXLexaria Bioscience-1.29%+10.73%-4.44%-42.99%-29.60%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTXContext Therapeutics$0.62-0.1%$1.53$0.55▼$3.62$57.31M1.754.25 million shs1.74 million shsEXOZeXoZymes$7.00+9.9%$8.61$6.13▼$18.40$58.67M2.7314,360 shs2,736 shsFLNACassava Sciences$1.09-5.2%$1.28$1.07▼$4.98$55.55M-0.73339,026 shs532,720 shsLEXXLexaria Bioscience$0.59-1.3%$0.60$0.46▼$1.55$14.75M0.3459,379 shs50,614 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTXContext Therapeutics-0.14%-11.01%-55.19%-75.18%-14.93%EXOZeXoZymes+9.89%-7.77%-1.41%-35.42%-28.64%FLNACassava Sciences-5.22%-16.79%-12.80%-31.45%-49.54%LEXXLexaria Bioscience-1.29%+10.73%-4.44%-42.99%-29.60%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNTXContext Therapeutics 2.89Moderate Buy$6.17889.99% UpsideEXOZeXoZymes 1.00SellN/AN/AFLNACassava Sciences 2.00Hold$5.00358.72% UpsideLEXXLexaria Bioscience 2.00Hold$1.50155.45% UpsideCurrent Analyst Ratings BreakdownLatest LEXX, EXOZ, CNTX, and FLNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/13/2026LEXXLexaria Bioscience Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/25/2026LEXXLexaria Bioscience Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/16/2026CNTXContext Therapeutics Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$8.00 ➝ $4.005/29/2026EXOZeXoZymes Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/26/2026FLNACassava Sciences Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.004/22/2026FLNACassava Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/22/2026LEXXLexaria Bioscience Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/20/2026CNTXContext Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 7/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNTXContext TherapeuticsN/AN/AN/AN/A$0.66 per shareN/AEXOZeXoZymes$70K921.00N/AN/A$0.40 per share17.50FLNACassava SciencesN/AN/AN/AN/A$1.54 per shareN/ALEXXLexaria Bioscience$710K20.50N/AN/A$0.13 per share4.52Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNTXContext Therapeutics-$36.12M-$0.42N/AN/AN/AN/A-59.95%-54.78%8/5/2026 (Estimated)EXOZeXoZymes-$9.16M-$1.14N/AN/AN/AN/A-220.63%-141.26%N/AFLNACassava Sciences-$90.97M-$1.61N/AN/AN/AN/A-53.90%-34.20%N/ALEXXLexaria Bioscience-$11.90M-$0.47N/AN/AN/AN/A-173.93%-138.79%N/ALatest LEXX, EXOZ, CNTX, and FLNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2026Q2 2026CNTXContext Therapeutics-$0.10N/AN/AN/AN/AN/A7/13/2026Q3 2026LEXXLexaria Bioscience-$0.06-$0.08-$0.02-$0.08$0.05 millionN/A5/14/2026Q1 2026EXOZeXoZymesN/A-$0.28N/A-$0.28N/AN/A5/7/2026Q1 2026FLNACassava SciencesN/A-$0.21N/A-$0.21N/AN/A5/6/2026Q1 2026CNTXContext Therapeutics-$0.12-$0.09+$0.03-$0.09N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCNTXContext TherapeuticsN/AN/AN/AN/AN/AEXOZeXoZymesN/AN/AN/AN/AN/AFLNACassava SciencesN/AN/AN/AN/AN/ALEXXLexaria BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNTXContext TherapeuticsN/A8.968.96EXOZeXoZymes0.031.321.32FLNACassava SciencesN/A2.192.19LEXXLexaria BioscienceN/A26.8426.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNTXContext Therapeutics14.03%EXOZeXoZymesN/AFLNACassava Sciences38.05%LEXXLexaria Bioscience13.06%Insider OwnershipCompanyInsider OwnershipCNTXContext Therapeutics4.80%EXOZeXoZymes72.41%FLNACassava Sciences4.60%LEXXLexaria Bioscience8.39%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNTXContext Therapeutics791.88 million87.47 millionNot OptionableEXOZeXoZymes299.21 million2.54 millionN/AFLNACassava Sciences2048.31 million46.09 millionOptionableLEXXLexaria Bioscience724.79 million22.71 millionNot OptionableLEXX, EXOZ, CNTX, and FLNA HeadlinesRecent News About These CompaniesLexaria Updates Business DevelopmentJuly 6, 2026 | accessnewswire.comALexaria Bioscience (LEXX) Projected to Announce Quarterly Earnings on MondayJuly 6, 2026 | americanbankingnews.comLexaria's Human Study GLP-1-H26-7 has Begun Dosing on ScheduleJune 25, 2026 | thenewswire.comTLexaria's Animal Study GLP-1-A26-1 has Begun Dosing on ScheduleJune 23, 2026 | thenewswire.comTLexaria Bioscience Corp.: GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to ExpandJune 19, 2026 | finanznachrichten.deGLP-1 "Arms Race" Intensifies as the Addressable Markets Continue to ExpandJune 17, 2026 | thenewswire.comTGLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to ExpandJune 17, 2026 | accessnewswire.comALexaria's Animal Study Examining Next-Generation GLP-1 drugs is UnderwayJune 9, 2026 | accessnewswire.comALexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway.June 9, 2026 | thenewswire.comTLexaria Attending the BIO International Convention, as Part of a Broader Business Development ProgramJune 3, 2026 | accessnewswire.comALexaria Attending the BIO International Convention, as part of a Broader Business Development ProgramJune 3, 2026 | thenewswire.comTLexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7May 19, 2026 | accessnewswire.comALexaria Bioscience Corp.: Lexaria Bioscience Releases Second Episode of Investor Video SeriesMay 7, 2026 | finanznachrichten.deLexaria Bioscience Releases Second Episode of Investor Video SeriesMay 7, 2026 | thenewswire.comTLexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder CommunicationsMay 1, 2026 | accessnewswire.comAMaterial Transfer Agreement Between Pharmaceutical Company and Lexaria is ExtendedApril 29, 2026 | accessnewswire.comALexaria Launches New Study to Examine Next-Generation GLP-1 DrugsApril 23, 2026 | thenewswire.comTLexaria Launches New Study to Examine Next-Generation GLP-1 DrugsApril 23, 2026 | accessnewswire.comALexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry SalesApril 21, 2026 | thenewswire.comTLexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry SalesApril 21, 2026 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeLEXX, EXOZ, CNTX, and FLNA Company DescriptionsContext Therapeutics NASDAQ:CNTX$0.62 0.00 (-0.14%) Closing price 07/14/2026 04:00 PM EasternExtended Trading$0.62 0.00 (-0.31%) As of 07:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.eXoZymes NASDAQ:EXOZ$7.00 +0.63 (+9.89%) Closing price 07/14/2026 04:00 PM EasternExtended Trading$6.54 -0.46 (-6.57%) As of 07/14/2026 05:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.Cassava Sciences NASDAQ:FLNA$1.09 -0.06 (-5.22%) As of 07/14/2026 04:00 PM EasternFilana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.Lexaria Bioscience NASDAQ:LEXX$0.59 -0.01 (-1.29%) Closing price 07/14/2026 04:00 PM EasternExtended Trading$0.60 +0.01 (+2.18%) As of 07:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet 3 Overlooked Energy ETFs Delivering Strong Returns and Income 3 Space Stocks That Could Outshine SpaceX After Its IPO 3 Energy Stocks Racing to Fix AI's Power Problem JPMorgan’s Q2 Strength Gives the Stock Rally New Support No Space For Panic: T-Mobile Shrugs Off The Starlink Threat Prepare for the Next Wave of Factory Automation With These 3 Standout Names Wedbush Pounds the Table—Buy Sandisk Before August 5 Earnings Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
